Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI

New York, NY, May 15th, 2025 (GLOBE NEWSWIRE) — Pathos AI, ( www.pathos.com ), a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion. This financing marks a major milestone for Pathos as it expands its AI-enabled platform to drive greater speed, precision, and success in oncology drug development. The proceeds will support advancement of the company’s clinical-stage pipeline and continued investment in its proprietary AI Foundatio